Utilization of new and innovative ovulation induction protocols sets Dr. Fox, Dr. Lipari and JCRM apart from typical reproductive endocrinology practice.  Their work on the underlying metabolic causes of Polycystic Ovarian Disease (PCOD) has yielded dramatic success rates.  Utilizing these new approaches, patients with PCOD at JCRM rarely need IVF or even more traditional forms of injectable drug therapy.  The vast majority of patients with this disease are becoming pregnant utilizing oral drugs in the first three cycles of treatment, many the first cycle. 

This new success reaches far beyond the successful pregnancy.  The ability to achieve pregnancy utilizing oral drug therapy reduces the multiple pregnancy risk significantly which is the number one objective for research in reproductive endocrinology on the national level.  Multiple pregnancy significantly increases the risk of prematurity and long term disabilities for the resulting infants.   Our goal for you is pregnancy but more important healthy children.  Additionally by reducing the intensity of therapy and the risk of multiples, the cost to the couple and the health care system as a whole is reduced dramatically. 

Ovulation induction refers to the use of medications and other treatments to aid or stimulate the development and release of an egg at the appropriate time in the menstrual cycle.  There are several different reasons for anovulation (not developing and releasing an egg).  Polycystic Ovarian Disease (PCOD) is the most common cause.  In other cases the signals from the brain to the ovary are interrupted such that egg development does not proceed.  General infertility testing most often reveals the causes of anovulation and aids in directing the appropriate treatments.  See attached subject pages for specific forms of ovulation induction.